$IMNM
Immunome Inc.

2021 Q4 Form 10-K Financial Statement

#000155837022004420 Filed on March 28, 2022

View on sec.gov

Income Statement

Concept 2021 Q4 2021 2020 Q4
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.459M $11.09M $2.240M
YoY Change 54.42% 132.09% 46.89%
% of Gross Profit
Research & Development $4.385M $14.11M $1.840M
YoY Change 138.32% 88.49% -79.15%
% of Gross Profit
Depreciation & Amortization $118.0K $800.0K $260.0K
YoY Change -54.62% 0.0% -18.75%
% of Gross Profit
Operating Expenses $7.844M $25.20M $4.070M
YoY Change 92.73% 105.56% -60.67%
Operating Profit -$25.20M
YoY Change 105.56%
Interest Expense -$5.000K -$10.00K $0.00
YoY Change -99.82% -100.0%
% of Operating Profit
Other Income/Expense, Net -$3.000K $493.0K
YoY Change -91.16%
Pretax Income -$7.852M -$24.71M -$4.070M
YoY Change 92.92% 38.51% -61.03%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$7.852M -$24.70M -$4.070M
YoY Change 92.92% 38.76% -61.03%
Net Earnings / Revenue
Basic Earnings Per Share -$2.14
Diluted Earnings Per Share -$648.5K -$2.14 -$381.8K
COMMON SHARES
Basic Shares Outstanding 12.10M 11.54M 10.54M
Diluted Shares Outstanding 11.54M

Balance Sheet

Concept 2021 Q4 2021 2020 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $49.23M $49.23M $39.77M
YoY Change 23.78% 23.78%
Cash & Equivalents $49.23M $39.77M
Short-Term Investments
Other Short-Term Assets $7.409M $7.409M $3.130M
YoY Change 136.71% 136.71%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $56.64M $56.64M $42.89M
YoY Change 32.04% 32.05% 1273.93%
LONG-TERM ASSETS
Property, Plant & Equipment $855.0K $855.0K $1.531M
YoY Change -44.15% -44.12% -9.94%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $432.0K $432.0K $100.0K
YoY Change 332.0% 332.0% -27.54%
Total Long-Term Assets $1.287M $1.287M $1.631M
YoY Change -21.09% -21.52% -15.84%
TOTAL ASSETS
Total Short-Term Assets $56.64M $56.64M $42.89M
Total Long-Term Assets $1.287M $1.287M $1.631M
Total Assets $57.93M $57.93M $44.53M
YoY Change 30.1% 30.08% 779.94%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.077M $3.077M $1.187M
YoY Change 159.22% 158.57% 116.61%
Accrued Expenses $6.651M $6.651M $1.372M
YoY Change 384.77% 385.47% 106.01%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00 $0.00 $366.0K
YoY Change -100.0% -100.0%
Total Short-Term Liabilities $9.728M $9.728M $3.038M
YoY Change 220.21% 220.0% 82.46%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $134.0K
YoY Change -100.0% -100.0%
Other Long-Term Liabilities $12.00K $12.00K $10.00K
YoY Change 20.0% 20.0%
Total Long-Term Liabilities $12.00K $12.00K $134.0K
YoY Change -91.04% -91.43%
TOTAL LIABILITIES
Total Short-Term Liabilities $9.728M $9.728M $3.038M
Total Long-Term Liabilities $12.00K $12.00K $134.0K
Total Liabilities $9.740M $9.740M $3.180M
YoY Change 206.29% 206.29% 77.06%
SHAREHOLDERS EQUITY
Retained Earnings -$79.11M -$54.40M
YoY Change 45.41% 48.63%
Common Stock $1.000K $1.000K
YoY Change 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $48.19M $48.19M $41.35M
YoY Change
Total Liabilities & Shareholders Equity $57.93M $57.93M $44.53M
YoY Change 30.1% 30.08% 779.94%

Cashflow Statement

Concept 2021 Q4 2021 2020 Q4
OPERATING ACTIVITIES
Net Income -$7.852M -$24.70M -$4.070M
YoY Change 92.92% 38.76% -61.03%
Depreciation, Depletion And Amortization $118.0K $800.0K $260.0K
YoY Change -54.62% 0.0% -18.75%
Cash From Operating Activities -$6.805M -$18.23M -$6.060M
YoY Change 12.29% 50.21% 22.67%
INVESTING ACTIVITIES
Capital Expenditures -$14.00K $79.00K -$50.00K
YoY Change -72.0% -86.52% -73.68%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$14.00K -$79.00K -$50.00K
YoY Change -72.0% -86.52% -73.68%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $41.70M $1.338M $41.70M
YoY Change 0.0% -97.02%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -195.0K 27.77M 39.13M
YoY Change -100.5% -44.4% 785.29%
NET CHANGE
Cash From Operating Activities -6.805M -18.23M -6.060M
Cash From Investing Activities -14.00K -79.00K -50.00K
Cash From Financing Activities -195.0K 27.77M 39.13M
Net Change In Cash -7.014M 9.463M 33.02M
YoY Change -121.24% -74.58% -4750.7%
FREE CASH FLOW
Cash From Operating Activities -$6.805M -$18.23M -$6.060M
Capital Expenditures -$14.00K $79.00K -$50.00K
Free Cash Flow -$6.791M -$18.31M -$6.010M
YoY Change 13.0% 43.91% 26.53%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.14
CY2020 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-5.26
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
11538668
CY2020 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3389592
CY2021 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
CY2020 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
CY2021Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
CY2020Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
CY2021 dei Amendment Flag
AmendmentFlag
false
CY2021 dei Entity Central Index Key
EntityCentralIndexKey
0001472012
CY2021 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
CY2021 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
12110373
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
10634245
CY2021 dei Document Type
DocumentType
10-K
CY2021 dei Document Annual Report
DocumentAnnualReport
true
CY2021 dei Document Period End Date
DocumentPeriodEndDate
2021-12-31
CY2021 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2021 dei Document Transition Report
DocumentTransitionReport
false
CY2021 dei Entity File Number
EntityFileNumber
001-39580
CY2021 dei Entity Registrant Name
EntityRegistrantName
IMMUNOME, INC.
CY2021 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2021 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
77-0694340
CY2021 dei Entity Address Address Line1
EntityAddressAddressLine1
665 Stockton Drive
CY2021 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 300
CY2021 dei Entity Address City Or Town
EntityAddressCityOrTown
Exton
CY2021 dei Entity Address State Or Province
EntityAddressStateOrProvince
PA
CY2021 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
19341
CY2021 dei City Area Code
CityAreaCode
610
CY2021 dei Local Phone Number
LocalPhoneNumber
321-3700
CY2021 dei Security12b Title
Security12bTitle
Common Stock, $0.0001 Par Value
CY2021 dei Trading Symbol
TradingSymbol
IMNM
CY2021 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2021 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2021 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2021 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2021 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2021 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2021 dei Entity Small Business
EntitySmallBusiness
true
CY2021 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2021 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2021 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2021 dei Entity Shell Company
EntityShellCompany
false
CY2021Q2 dei Entity Public Float
EntityPublicFloat
182300000
CY2022Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
12127385
CY2021 dei Auditor Firm
AuditorFirmId
34
CY2021 dei Auditor Name
AuditorName
Deloitte & Touche LLP
CY2021 dei Auditor Location
AuditorLocation
Philadelphia, Pennsylvania
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
49229000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
39766000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
7409000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3128000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
56638000
CY2020Q4 us-gaap Assets Current
AssetsCurrent
42894000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
855000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1531000
CY2021Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
100000
CY2020Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
100000
CY2021Q4 us-gaap Deferred Costs
DeferredCosts
332000
CY2021Q4 us-gaap Assets
Assets
57925000
CY2020Q4 us-gaap Assets
Assets
44525000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3077000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1187000
CY2021Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
6651000
CY2020Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
1372000
CY2020Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
366000
CY2020Q4 imnm Current Portion Of Equipment Loan Payable
CurrentPortionOfEquipmentLoanPayable
113000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
9728000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
3038000
CY2020Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
134000
CY2021Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
12000
CY2020Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
8000
CY2021Q4 us-gaap Liabilities
Liabilities
9740000
CY2020Q4 us-gaap Liabilities
Liabilities
3180000
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
12110373
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
10634245
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
1000
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
1000
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
127289000
CY2020Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
95738000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-79105000
CY2020 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-5576000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-24711000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-17837000
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.14
CY2020 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-5.26
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
11538668
CY2020 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3389592
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
-35630000
CY2020 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
48369000
CY2020 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
7060000
CY2020 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
6108000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-54394000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
48185000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
41345000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
57925000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
44525000
CY2021 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
14110000
CY2020 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7486000
CY2021 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
11094000
CY2020 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4775000
CY2021 us-gaap Operating Expenses
OperatingExpenses
25204000
CY2020 us-gaap Operating Expenses
OperatingExpenses
12261000
CY2021 us-gaap Operating Income Loss
OperatingIncomeLoss
-25204000
CY2020 us-gaap Operating Income Loss
OperatingIncomeLoss
-12261000
CY2020 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
5538000
CY2021 us-gaap Other Income
OtherIncome
503000
CY2021 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-10000
CY2020 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-38000
CY2021 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
493000
CY2020 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
38742000
CY2020 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
621000
CY2020 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
20000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-17837000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
41345000
CY2021 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
559000
CY2021 imnm Stock Issued During Period Value Common Stock And Warrants
StockIssuedDuringPeriodValueCommonStockAndWarrants
26666000
CY2021 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3448000
CY2021 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
1338000
CY2021 imnm Stock Issued During Period Value Stock Options Exercised And Vesting Of Restricted Stock
StockIssuedDuringPeriodValueStockOptionsExercisedAndVestingOfRestrictedStock
99000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-24711000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
48185000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-24711000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-17837000
CY2021 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
755000
CY2020 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
755000
CY2021 us-gaap Share Based Compensation
ShareBasedCompensation
3448000
CY2020 us-gaap Share Based Compensation
ShareBasedCompensation
621000
CY2020 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
5538000
CY2021 imnm Deferred Rent
DeferredRent
4000
CY2020 imnm Deferred Rent
DeferredRent
-2000
CY2021 imnm Forgiveness Of Ppp Loan
ForgivenessOfPppLoan
-500000
CY2021 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
4281000
CY2020 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2411000
CY2021 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1780000
CY2020 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
504000
CY2021 imnm Increase Decrease In Accrued Expenses And Other Current Liabilities
IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities
5279000
CY2020 imnm Increase Decrease In Accrued Expenses And Other Current Liabilities
IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities
698000
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-18226000
CY2020 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-12134000
CY2021 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
79000
CY2020 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
586000
CY2021 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-79000
CY2020 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-586000
CY2021 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
99000
CY2020 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
20000
CY2021 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
1338000
CY2020 us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
500000
CY2021 imnm Proceeds From Issuance Of Common Stock And Warrants
ProceedsFromIssuanceOfCommonStockAndWarrants
27225000
CY2020 imnm Proceeds From Issuance Of Common Stock And Warrants
ProceedsFromIssuanceOfCommonStockAndWarrants
44850000
CY2021 imnm Payments Of Common Stock And Warrants Issuance Costs
PaymentsOfCommonStockAndWarrantsIssuanceCosts
559000
CY2020 imnm Payments Of Common Stock And Warrants Issuance Costs
PaymentsOfCommonStockAndWarrantsIssuanceCosts
5973000
CY2020 us-gaap Proceeds From Issuance Of Convertible Preferred Stock
ProceedsFromIssuanceOfConvertiblePreferredStock
11046000
CY2020 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
49000
CY2021 imnm Repayments Of Equipment Loan
RepaymentsOfEquipmentLoan
113000
CY2020 imnm Repayments Of Equipment Loan
RepaymentsOfEquipmentLoan
212000
CY2020 imnm Repayments Of Capital Lease Obligations
RepaymentsOfCapitalLeaseObligations
239000
CY2021 imnm Payment Of Offering Costs
PaymentOfOfferingCosts
222000
CY2021 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
27768000
CY2020 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
49943000
CY2021 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
9463000
CY2020 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
37223000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
39866000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2643000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
49329000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
39866000
CY2021 us-gaap Interest Paid Net
InterestPaidNet
14000
CY2020 us-gaap Interest Paid Net
InterestPaidNet
29000
CY2020 us-gaap Conversion Of Stock Amount Issued1
ConversionOfStockAmountIssued1
48369000
CY2021 imnm Offering Cost In Accounts Payable
OfferingCostInAccountsPayable
110000
CY2020 imnm Offering Cost In Accounts Payable
OfferingCostInAccountsPayable
135000
CY2020 imnm Liability Classified Warrants Issued In Connection With Convertible Preferred Stock Fair Value
LiabilityClassifiedWarrantsIssuedInConnectionWithConvertiblePreferredStockFairValue
1522000
CY2020 imnm Conversion Of Liability Classified Warrants
ConversionOfLiabilityClassifiedWarrants
7060000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-24700000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-17800000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-79100000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-54400000
CY2021 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Use of estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities and expenses. The Company bases its estimates and assumptions on historical experience when available and on various factors that it believes to be reasonable under the circumstances. Significant estimates and assumptions reflected in these financial statements include, but are not limited to, the fair value of the Company’s common stock prior to its IPO, in connection with share-based compensation arrangements, the expected volatility used to estimate fair value of common stock, services performed but not billed relating to research and development contracts, and services performed on research and development advanced payments. Estimates and assumptions are periodically reviewed in-light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ from these estimates.</p>
CY2021 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2020Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
100000
CY2021Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
100000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
49229000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
39766000
CY2021Q4 us-gaap Restricted Cash
RestrictedCash
100000
CY2020Q4 us-gaap Restricted Cash
RestrictedCash
100000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
49329000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
39866000
CY2021Q4 imnm Fair Value Of Common Stock
FairValueOfCommonStock
23.04
CY2020Q4 imnm Fair Value Of Common Stock
FairValueOfCommonStock
5.30
CY2021 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Concentration of Credit Risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Financial instruments that potentially subject the Company to significant concentration of credit risk consist primarily of cash and cash equivalents. Periodically, the Company may maintain deposits in financial institutions in excess of government insured limits. Management believes that the Company is not exposed to significant credit risk as the Company’s deposits are held at financial institutions that management believes to be of high credit quality, and the Company has not experienced any losses on these deposits.</p>
CY2020 imnm Research And Development Milestone Expense
ResearchAndDevelopmentMilestoneExpense
0
CY2021 imnm Research And Development Milestone Expense
ResearchAndDevelopmentMilestoneExpense
0
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2020 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2021 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2021Q4 us-gaap Deferred Offering Costs
DeferredOfferingCosts
300000
CY2020Q4 us-gaap Deferred Offering Costs
DeferredOfferingCosts
0
CY2020 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
5500000
CY2021 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3308868
CY2020 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2508036
CY2021Q4 imnm Reimbursement Receivable Current
ReimbursementReceivableCurrent
2674000
CY2020Q4 imnm Reimbursement Receivable Current
ReimbursementReceivableCurrent
850000
CY2021Q4 us-gaap Prepaid Insurance
PrepaidInsurance
2019000
CY2020Q4 us-gaap Prepaid Insurance
PrepaidInsurance
1767000
CY2021Q4 imnm Unbilled Reimbursement Receivable Current
UnbilledReimbursementReceivableCurrent
1638000
CY2021Q4 imnm Research And Development Expense Advance Payments
ResearchAndDevelopmentExpenseAdvancePayments
586000
CY2021Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
492000
CY2020Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
511000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
7409000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3128000
CY2021Q4 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset Before Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
3884000
CY2020Q4 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset Before Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
3805000
CY2021Q4 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization
3029000
CY2020Q4 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization
2274000
CY2021Q4 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
855000
CY2020Q4 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
1531000
CY2020 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
800000
CY2021 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
800000
CY2020Q4 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
0
CY2021Q4 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
0
CY2021Q4 imnm Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
2840000
CY2020Q4 imnm Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
9000
CY2021Q4 imnm Deferred Research Obligations Liabilities Current
DeferredResearchObligationsLiabilitiesCurrent
2021000
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1246000
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
845000
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
227000
CY2020Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
417000
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
317000
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
101000
CY2021Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
6651000
CY2020Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
1372000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
257000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
246000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
63000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
566000
CY2021 us-gaap Payments For Rent
PaymentsForRent
500000
CY2020 us-gaap Payments For Rent
PaymentsForRent
400000
CY2020 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
100000
CY2021 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
100000
CY2021Q4 imnm Collaborative Arrangements Product Development And Regulatory Approval Milestone Payments Payable
CollaborativeArrangementsProductDevelopmentAndRegulatoryApprovalMilestonePaymentsPayable
2600000
CY2021Q4 imnm Collaborative Arrangements Commercial Milestone Payments Payable
CollaborativeArrangementsCommercialMilestonePaymentsPayable
1500000
CY2021 imnm Common Stock Voting Right
CommonStockVotingRight
1
CY2021Q3 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
14115
CY2021Q3 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
15.94
CY2021Q4 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
41700000
CY2021Q4 imnm Payments Of Underwriting Discounts And Commissions
PaymentsOfUnderwritingDiscountsAndCommissions
3100000
CY2021 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3448000
CY2020 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
621000
CY2021Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
13300000
CY2021 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P3Y4M24D
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.830
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.830
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.010
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.006
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y1M6D
CY2020Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
0
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
8.69
CY2021 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2020 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2021 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.080
CY2020 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.058
CY2021 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Research And Development
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment
0.024
CY2020 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Research And Development
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment
0.009
CY2021 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Other
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther
0.003
CY2020 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Other
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther
-0.068
CY2021 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.317
CY2020 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.209
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
19925000
CY2020Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
13693000
CY2021Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
2157000
CY2020Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
1560000
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
886000
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
82000
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Bonuses
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses
331000
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Bonuses
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses
201000
CY2021Q4 imnm Deferred Tax Assets Amortization
DeferredTaxAssetsAmortization
1000
CY2020Q4 imnm Deferred Tax Assets Amortization
DeferredTaxAssetsAmortization
2000
CY2021Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
23300000
CY2020Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
15538000
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
23255000
CY2020Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
15435000
CY2021Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
45000
CY2020Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
103000
CY2021Q4 imnm Deferred Tax Assets Depreciation
DeferredTaxAssetsDepreciation
45000
CY2020Q4 imnm Deferred Tax Assets Depreciation
DeferredTaxAssetsDepreciation
103000
CY2020 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2021 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
7800000
CY2020 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
3700000
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Domestic
DeferredTaxAssetsOperatingLossCarryforwardsDomestic
68800000
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards State And Local
DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
69200000
CY2020Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Domestic
DeferredTaxAssetsOperatingLossCarryforwardsDomestic
47300000
CY2020Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards State And Local
DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
47700000
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Not Subject To Expiration
DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration
51800000
CY2020 imnm Net Operating Loss Carryforwards Offset Percent Of Taxable Income Maximum Percentage
NetOperatingLossCarryforwardsOffsetPercentOfTaxableIncomeMaximumPercentage
0.80
CY2020Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2020 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
0
CY2021 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
0

Files In Submission

Name View Source Status
0001558370-22-004420-index-headers.html Edgar Link pending
0001558370-22-004420-index.html Edgar Link pending
0001558370-22-004420.txt Edgar Link pending
0001558370-22-004420-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tmb-20211231.xsd Edgar Link pending
tmb-20211231x10k.htm Edgar Link pending
tmb-20211231x10k001.jpg Edgar Link pending
tmb-20211231x10k002.jpg Edgar Link pending
tmb-20211231x10k003.jpg Edgar Link pending
tmb-20211231x10k004.jpg Edgar Link pending
tmb-20211231x10k005.jpg Edgar Link pending
tmb-20211231x10k006.jpg Edgar Link pending
tmb-20211231x10k007.jpg Edgar Link pending
tmb-20211231x10k008.jpg Edgar Link pending
tmb-20211231x10k009.jpg Edgar Link pending
tmb-20211231x10k010.jpg Edgar Link pending
tmb-20211231x10k011.jpg Edgar Link pending
tmb-20211231x10k012.jpg Edgar Link pending
tmb-20211231x10k013.jpg Edgar Link pending
tmb-20211231x10k014.jpg Edgar Link pending
tmb-20211231x10k015.jpg Edgar Link pending
tmb-20211231x10k016.jpg Edgar Link pending
tmb-20211231x10k_htm.xml Edgar Link completed
tmb-20211231xex10d28.htm Edgar Link pending
tmb-20211231xex23d1.htm Edgar Link pending
tmb-20211231xex31d1.htm Edgar Link pending
tmb-20211231xex31d2.htm Edgar Link pending
tmb-20211231xex32d1.htm Edgar Link pending
tmb-20211231xex32d2.htm Edgar Link pending
tmb-20211231xex4d6.htm Edgar Link pending
tmb-20211231_cal.xml Edgar Link unprocessable
tmb-20211231_def.xml Edgar Link unprocessable
tmb-20211231_lab.xml Edgar Link unprocessable
tmb-20211231_pre.xml Edgar Link unprocessable